Evotec SE
HealthcareNASDAQ:EVO · NASDAQ Global Select
+$0.00 today
Vol 0.01M · Avg 0.09M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$745.2M of revenue converted into -$196.0M of net income for the selected period. Gross margin is 8.7% and net margin is -30.9%, showing how much revenue survives after costs and taxes. EPS is $-0.55, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $757.3M -5.0% | $797.0M +2.0% | $781.4M +4.0% | $751.4M +21.6% | $618.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $694.6M +1.8% | $682.1M +12.5% | $606.4M +5.0% | $577.4M +23.8% | $466.5M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $62.7M -45.5% | $114.9M -34.4% | $175.1M +0.6% | $174.1M +14.9% | $151.5M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 8.3% -6.1pp | 14.4% -8.0pp | 22.4% -0.8pp | 23.2% -1.4pp | 24.5% | 9.8% | 28.9% | 38.3% |
| Research & Development | $74.3M +46.2% | $50.9M -25.8% | $68.5M -10.6% | $76.6M +16.7% | $65.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $123.6M -34.3% | $188.2M +11.0% | $169.6M +8.6% | $156.2M +48.1% | $105.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $198.0M -23.1% | $257.4M +15.7% | $222.6M +45.3% | $153.2M +38.6% | $110.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $95.5M -6.0% | $101.6M +9.3% | $93.0M +11.8% | $83.2M +18.2% | $70.4M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$13.9M +82.8% | -$80.7M -434.3% | $24.1M +141.9% | -$57.6M -118.2% | $316.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -1.8% +8.3pp | -10.1% -13.2pp | 3.1% +10.8pp | -7.7% -58.9pp | 51.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$135.3M +5.1% | -$142.5M -200.0% | -$47.5M -327.9% | $20.9M -49.1% | $41.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -17.9% +0.0pp | -17.9% -11.8pp | -6.1% -8.9pp | 2.8% -3.9pp | 6.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $4.2M +74.5% | $2.4M -73.7% | $9.3M +11.1% | $8.3M +266.9% | $2.3M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $13.9M +18.6% | $11.7M -0.3% | $11.7M -10.7% | $13.2M +42.1% | $9.3M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $12.0M +123.3% | -$51.5M -55.5% | -$33.1M +81.1% | -$174.8M -189.2% | $196.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$123.3M +36.4% | -$194.0M -140.7% | -$80.6M +47.7% | -$154.0M -165.0% | $237.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -16.3% +8.1pp | -24.3% -14.0pp | -10.3% +10.2pp | -20.5% -58.8pp | 38.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$23.9M -1236.1% | $2.1M -36.7% | $3.3M -84.7% | $21.7M +1.1% | $21.5M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$99.4M +49.3% | -$196.1M -133.7% | -$83.9M +52.2% | -$175.7M -181.5% | $215.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | -13.1% +11.5pp | -24.6% -13.9pp | -10.7% +12.6pp | -23.4% -58.2pp | 34.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +50.0% | -$1 -143.5% | -$0 +53.1% | -$0 -175.4% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +50.0% | -$1 -143.5% | -$0 +53.1% | -$0 -175.4% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $355.2M +0.5% | $353.3M -0.2% | $353.9M +0.1% | $353.3M +6.2% | $332.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $355.2M +0.2% | $354.6M +0.2% | $353.9M +0.1% | $353.4M +6.2% | $332.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$4.88B
Pharvaris N.V.
NASDAQ:PHVS
$2.15B
NovoCure Limited
NASDAQ:NVCR
$2.06B
Harrow Health, Inc.
NASDAQ:HROW
$1.40B
Teladoc Health, Inc.
NYSE:TDOC
$1.32B
Alvotech
NASDAQ:ALVO
$1.30B
Schrödinger, Inc.
NASDAQ:SDGR
$1.08B
Azenta, Inc.
NASDAQ:AZTA
$1.04B
Pacira BioSciences, Inc.
NASDAQ:PCRX
$904.31M
Tilray Brands, Inc.
NASDAQ:TLRY
$595.63M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does EVO generate?
Evotec SE (EVO) reported $757.26M of revenue in fiscal 2025.
Is EVO profitable?
Evotec SE (EVO) reported -$99,431,462.00 of net income, with a net margin of -13.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.